Page last updated: 2024-09-05

sorafenib and homoharringtonine

sorafenib has been researched along with homoharringtonine in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (homoharringtonine)	Trials (homoharringtonine)	Recent Studies (post-2010) (homoharringtonine)
6,520	730	5,251	501	53	255

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Au, CH; Chan, TL; Cher, CY; Cheung, AM; Gill, H; He, BL; Ho, DN; Ho, ES; Ip, HW; Kwong, YL; Lam, SS; Leung, AY; Liang, R; Ma, ES; Man, CH; Ng, NK; So, CC; So, CW; Tamburini, J; Wong, WW	1
Au, CH; Chan, TL; Ip, HW; Kwong, YL; Lam, SSY; Lau, JSM; Lee, HKK; Leung, AYH; Leung, GMK; Li, W; Luk, TH; Ma, ESK; Ng, NKL; Tsui, SP; Yang, N; Yip, SF; Zhang, C	1

Trials

2 trial(s) available for sorafenib and homoharringtonine

Article	Year
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Science translational medicine, 2016, 10-05, Volume: 8, Issue:359 Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Culture Techniques; Cell Line, Tumor; Cluster Analysis; Drug Evaluation, Preclinical; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Remission Induction; Sorafenib; Treatment Outcome; Young Adult	2016
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. Cancer, 2020, 01-15, Volume: 126, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Exons; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleophosmin; Remission Induction; Sorafenib; Transplantation, Homologous; Young Adult	2020

Article

Year

Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.

Science translational medicine, 2016, 10-05, Volume: 8, Issue:359

Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Culture Techniques; Cell Line, Tumor; Cluster Analysis; Drug Evaluation, Preclinical; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Remission Induction; Sorafenib; Treatment Outcome; Young Adult

2016

Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.

Cancer, 2020, 01-15, Volume: 126, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Exons; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleophosmin; Remission Induction; Sorafenib; Transplantation, Homologous; Young Adult

2020